Boston – October 06, 2026 -- Luminous Mind, Inc. (LMI) has secured U.S. Patent No. 12,697,362, covering technology that produces non-hallucinogenic psychedelic fungi, targeting a functional mushroom market Grand View Research values at $38.2 billion for 2025.
Patent strips psilocybin while preserving secondary metabolites
The patent isolates beneficial compounds found in psilocybin-containing mushrooms -- secondary metabolites and active fungal molecules typically overshadowed by the hallucinogen. By removing psilocybin, LMI says the resulting products retain potential nutraceutical benefits without triggering hallucinations, opening a path to mass-market commercialization that psychedelic-based products cannot access under current regulatory frameworks.
CEO compares breakthrough to domestication of toxic food crops
Louis Herlands, Ph.D., CEO of LMI, said the invention could make the nutraceutical benefits of biosynthetically complex mushrooms broadly accessible, likening the process to the historical domestication of tomatoes and potatoes from toxic wild varieties.
Genetics lead says technology scales rare compounds for the first time
Myles Axton, Ph.D., a genetics researcher at LMI and former Chief Editor of Nature Genetics, said the innovation allows mushrooms to produce useful levels of more than a dozen compounds that would otherwise appear only in trace amounts in psychedelic fungi or require restricted laboratory conditions to isolate.
Company seeks nutraceutical, pharma and venture partners
LMI is inviting nutraceutical, supplement, pharmaceutical and venture groups to pursue strategic partnerships for bringing the resulting product candidates to market. The company frames the patent as a near-term commercial opportunity in consumer nutraceuticals, with longer-term potential for synthetic-biology-derived pharmaceuticals targeting central nervous system disorders.